<DOC>
	<DOCNO>NCT02471846</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics combination GDC-0919 atezolizumab participant locally advance , recurrent , metastatic incurable solid malignancy progress available standard therapy standard therapy ineffective , intolerable , inappropriate . Participants enrol two stage , include dose-escalation stage expansion stage .</brief_summary>
	<brief_title>A Study GDC-0919 Atezolizumab Combination Treatment Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Adequate hematologic end organ function Negative pregnancy test willingness utilize contraception among woman childbearing potential Locally advance , recurrent , metastatic incurable solid malignancy measurable disease per RECIST v1.1 Progression follow least one standard therapy ; standard therapy consider ineffective , intolerable , inappropriate ; use investigational agent recognize standard care For expansion stage , histologically confirm renal cell cancer ( RCC ) , urothelial bladder cancer ( UBC ) , triplenegative breast cancer ( TNBC ) , nonsmall cell lung cancer ( NSCLC ) , melanoma , head neck squamous cell carcinoma ( HNSCC ) , gastric cancer , ovarian cancer , cervical cancer , endometrial cancer , Merkel cell cancer For expansion stage , evaluable PDL1 expression Anti PD1/PDL1 relapse cohort ( I II ) , participant whose recent anticancer therapy consist singleagent PD1/PDL1 blockade enrol Significant cardiovascular liver disease Major surgery within 28 day study drug Any anticancer therapy within 3 week study drug Malabsorption syndrome poor upper gastrointestinal integrity Primary central nervous system ( CNS ) malignancy active metastasis within 5 year Uncontrolled tumor pain Autoimmune disease stable hypothyroidism vitiligo Human immunodeficiency virus ( HIV ) , active hepatitis B C , tuberculosis Signs/symptoms infection , use antibiotic within 2 week study drug Live attenuate vaccine within 4 week study drug Known history predisposition QT interval prolongation Prior cancer immunotherapy , specifically indoleamine 2,3dioxygenase ( IDO ) tryptophan 2,3dioxygenase ( TDO ) inhibitor , Tcell costimulatory receptor agonist antibody , checkpoint inhibitor among certain participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>